Ceramidase critically affects GPVI-dependent platelet activation and thrombus formation

Platelet function is influenced by sphingolipids such as ceramide and sphingosine. These molecules are part of a complex metabolic network involving ceramide synthases and ceramidases. Prior research has shown that sphingosine and ceramide regulate platelet aggregation and thrombus formation. However, the specific roles of ceramide synthase and ceramidase in platelet signaling remained unclear. No prior work had resolved how these enzymes impact glycoprotein VI (GPVI)-dependent platelet activation. This gap motivated the current investigation into the effects of ceramidase inhibition. The study aimed to clarify whether ceramidase activity is essential for sphingosine-dependent platelet function. Understanding these mechanisms could improve models of thrombosis and bleeding disorders. The findings may help distinguish between sphingolipid pathways that are critical versus those that are redundant.

This study aimed to determine the role of ceramide synthase and ceramidase in GPVI-dependent platelet function. The researchers focused on how these enzymes affect platelet aggregation and thrombus formation. They used pharmacological inhibitors to block serine palmitoyltransferase, ceramide synthase, and ceramidase. The goal was to assess whether these enzymes are necessary for sphingosine-induced platelet activation. The study also sought to determine if exogenous sphingosine could restore platelet function after ceramidase inhibition. The motivation was to clarify the specific contribution of ceramidase to platelet signaling. The findings could help identify which sphingolipid pathways are most relevant to platelet function. This work may inform future studies on antiplatelet therapies and sphingolipid metabolism.

The study used transmission light aggregometry to measure platelet aggregation. Luciferase-based ATP release measurements were employed to assess dense granule secretion. In vitro thrombus formation was studied under high arterial shear rates. Pharmacological inhibitors were used to block serine palmitoyltransferase, ceramide synthase, and ceramidase. Platelet responses were tested using collagen-related peptide (CRP) stimulation. The experiments were conducted on collagen-coated surfaces under shear rates of 1700 s⁻¹. Exogenous sphingosine was added to determine if it could restore platelet function after ceramidase inhibition. The methods allowed a direct comparison of the effects of each enzyme's inhibition on platelet behavior.

Inhibition of ceramidase significantly reduced CRP-induced GPVI-dependent platelet aggregation. ATP release was also diminished following ceramidase inhibition. Thrombus formation on collagen surfaces was impaired under high shear rates after ceramidase inhibition. Exogenous sphingosine partially restored platelet aggregation after ceramidase inhibition. These findings suggest that ceramidase-derived sphingosine is essential for platelet function. In contrast, inhibition of serine palmitoyltransferase had no significant effect on platelet activation. Similarly, ceramide synthase inhibition did not alter GPVI-dependent responses. The results highlight the specific role of ceramidase in sphingosine signaling.

The study concludes that ceramidase plays a crucial role in sphingosine-induced platelet activation. The findings suggest that ceramidase-derived sphingosine is necessary for GPVI-dependent signaling. Exogenous sphingosine partially restores platelet function after ceramidase inhibition. These results indicate that ceramidase is a key player in sphingolipid metabolism related to platelet function. The study does not assign essentiality to ceramide synthase or serine palmitoyltransferase in this context. The authors propose that ceramidase activity is critical for maintaining sphingosine levels in platelets. The findings may guide future research on sphingolipid pathways in thrombosis. The study does not suggest broader implications beyond the specific role of ceramidase.